Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29

Cullinan Therapeutics, Inc.

Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.
Cash and investments $468.3M; runway expected into H2 2026.
On track to report CLN-619 combo/monotherapy data at a medical meeting in Q2 2024.
Received FDA IND clearance for CLN-619 in multiple myeloma; exploring CLN-978 in autoimmune diseases.
CFO Jeff Trigilio to depart effective March 29, 2024, with transition support.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cullinan Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, Cullinan Oncology, Inc. announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.